PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost lymphoma treatment
Disease control OngoingThis phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot shows promise against tough lymphoma in japanese study
Disease control OngoingThis trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to boost survival in kids with aggressive lymphoma
Disease control OngoingThis study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells target tough blood cancers in new trial
Disease control OngoingThis study tests FDA-approved CAR-T cell therapy in 150 children and adults with certain blood cancers that have come back or not responded to treatment. Participants receive their own immune cells that have been reprogrammed to attack cancer cells. The goal is to see how many pa…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental donor immune cells target Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered donor cells take on tough lymphomas and leukemias
Disease control OngoingThis early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells primed with decitabine show promise for tough lymphoma
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC
-
15-Year watch begins for new cancer cell therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC